Corona Remedies IPO IPO Analysis: Complete Investment Guide
Corona Remedies IPO is ongoing for subscription. This comprehensive analysis covers all aspects including GMP trends, subscription status, financial performance, and AI-powered investment rating to help you make an informed decision.
IPO Details at a Glance
| Parameter | Details |
|---|---|
| Company Name | Corona Remedies IPO |
| Issue Size | ₹655.37 Cr |
| Price Band | ₹1008.0 - ₹1062.0 |
| Lot Size | 14 shares |
| Issue Opens | 8 Dec 2025 |
| Issue Closes | 10 Dec 2025 |
| Listing Date | 15 Dec 2025 |
AI-Powered Investment Rating
AI Investment Rating
- ✅ Good subscription levels indicate positive market sentiment
- ⚠️ Expensive valuation - limited room for gains
- 📈 Moderate listing gains possible (5-12%)
- ⚠️ Average financials - growth could be better
- 👍 Good GMP level, moderate listing gains likely (8-12%)
✅ Apply by DAY 2-3 - Moderate demand, reasonable allotment probability
Company Overview
Corona Remedies Limited is an India-focused branded pharmaceutical company specializing in developing and marketing products across high-growth chronic therapeutic areas, primarily women’s healthcare, cardio-diabeto, pain management, and urology. The company is recognized as the second-fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) by domestic sales. It operates two manufacturing facilities in Gujarat and Himachal Pradesh and leverages a pan-India marketing network of 2,671 medical representatives.
Grey Market Premium (GMP) Analysis
Subscription Status
Investment Recommendation
AI Investment Rating
- 👍 CONSIDER - Decent opportunity for diversification
- Lot Size: Apply 1-2 lots based on risk appetite
- Bid Price: Bid at CUT-OFF price
- Risk Level: MEDIUM
Important Dates
| Event | Date |
|---|---|
| Issue Opens | 8 Dec 2025 |
| Issue Closes | 10 Dec 2025 |
| Allotment | 11 Dec 2025 |
| Listing Date | 15 Dec 2025 |
Investment Disclaimer
This analysis is for informational purposes only. Please consult with a SEBI-registered financial advisor before making investment decisions. Past performance does not guarantee future results.